Mind Medicine Begins Phase 2B Study On Treating Generalized Anxiety Disorder With LSD Variant

Mind Medicine (NEO: MMED) has officially seen patient trials under a Phase 2b study get underway as it looks to find a treatment for generalized anxiety disorder. The firm this morning indicated it has begun dosing its first patients with one of its novel formulations.

The novel drug being tested under the clinical trial is referred to as MM-120, which the company classifies as a “pharmaceutically optimized” version of what is referred to as LSD. Mindmed classifies the drug as its lead candidate, with the drug having potential uses across multiple therapeutic areas in addition to generalized anxiety disorder, such as psychiatry, pain, and substance use disorders.

The current study looks to determine if a reduction in anxiety symptoms is present four weeks after a single dose of the drug, with secondary objectives such as assessments of quality of life, safety, and tolerability to be measured after twelve weeks.

“The initiation of our Phase 2b clinical trial, the largest well-controlled clinical trial of LSD ever conducted, represents a major milestone for MindMed and for the many patients suffering from GAD. This exciting next step in the advancement of LSD builds on the positive topline data presented by our partners at University Hospital Basel in May 2022, which demonstrated the rapid, durable, and statistically significant effects of LSD and its potential to safely mitigate symptoms of anxiety and depression,” stated CEO Robert Barrow.

The trial itself is set to be conducted on a total of 200 patients, with dosages of MM-120 ranging to upwards of 200 µg to be delivered to patients on a randomized basis, or placebo. The study is also looking to identify dose optimization for further trials, with the trial to guide dose selection and development of the Phase 3 trials for the drug.

The development follows the firm earlier this month filing its second quarter financial results, which were highlighted by a cash position of US$105.7 million.

Mind Medicine last traded at $1.14 on the Neo.


Information for this briefing was found via Edgar and MindMed. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Leave a Reply

Video Articles

Endeavour Mining Q1 Earnings: Cash Flow Is King

G Mining Oko West Feasibility: Move Fast, Break.. Nothing?

New Gold Q1 Earnings: What’s Behind The Market’s Surprising Reaction?

Recommended

First Majestic Posts Record Cash Flows In Q1 As Production Costs Fall

Brazil Potash Secures Funding In Support Of US$2.5 Billion Autozales Project

Related News

Mind Medicine Announces $10.0 Million Bought Deal At Large Discount To Share Price

Mind Medicine (NEO: MMED) this morning announced a bought deal financing with Eight Capital as...

Tuesday, May 5, 2020, 09:14:31 AM

MindMed Launches R(-)-MDMA Program For Autism Spectrum Disorder Symptoms

Mind Medicine Inc. (NEO: MMED), more commonly known as MindMed, recently launched a program to...

Tuesday, October 26, 2021, 10:35:00 AM

MindMed Launches Clinical Trial Focused On Combining LSD With MDMA

Mind Medicine (NEO: MMED) has begun the first clinical trials focused on combining MDMA and...

Wednesday, January 20, 2021, 08:09:53 AM

Mind Medicine Boasts Current Cash Position Of US$161 Million

Mind Medicine (NEO: MMED) this morning released its fiscal year 2020 financial results. Given that...

Tuesday, March 30, 2021, 08:19:57 AM

Mind Medicine Sees FDA Place Clinical Hold On Phase 2b Study

Mind Medicine (NEO: MMED) this morning indicated that things are not going quite to plan...

Tuesday, December 21, 2021, 08:22:51 AM